Scientific Director of Clinical Research Collaborations, Medical Evidence Generation Team, Department of Global Medical Affairs, Bristol Myers Squibb

Dr. Kate Barrientos is a research scientist with over 15 years of broad experience in the pharmaceutical industry, with a primary focus in oncology drug development. Her current title is Scientific Director of Clinical Research Collaborations within the Medical Evidence Generation Team in the Global Medical Affairs Department of Bristol Myers Squibb (BMS) in Princeton, N.J. Prior to this role, Kate has worked across a wide scope of departments at BMS including Precision Medicine, Translational Pathology, and Global Product Development & Supply through which she gained diverse experiences in driving the development and strategy for many key clinical immuno-oncology, cell therapy, and targeted oncology assets within the BMS pipeline. Prior to joining BMS, Kate was an Investigator at GlaxoSmithKline and led a team of immunoassay scientists to develop and validate potency assays for clinical biologics molecules in oncology.

Kate earned her Bachelor of Science degree from Penn State in Biology and worked in the laboratory of Dr. Jack Vanden Heuvel within the Department of Veterinary and Biomedical Sciences as an undergraduate. She earned her PhD in Pharmacology and Cancer Biology from Duke University working in the laboratory of Dr. Christopher Counter studying the roles of telomere-binding protein complexes and completed a joint postdoctoral fellowship with Duke University and GlaxoSmithKline investigating nitric oxide synthase inhibition in pancreatic and other KRas-driven cancers.